An implantable medical lead includes a lead body having a proximal portion having a longitudinal axis and an arcuate distal body portion extending in the direction of the longitudinal axis. The arcuate distal body portion has a concave surface. The lead includes a plurality of elongate electrodes disposed at the arcuate distal end portion of the lead body along the concave surface. The electrodes extend substantially parallel to the longitudinal axis of the lead body.
|
1. An implantable medical lead comprising: a lead body including (i) a proximal portion having a longitudinal axis, and (ii) an arcuate distal portion extending in the direction of the longitudinal axis, the arcuate distal portion having a concave surface; and
a plurality of elongate electrodes disposed at the arcuate distal portion of the lead body along the concave surface, the electrodes extending substantially parallel to the longitudinal axis of the lead body,
wherein the plurality of electrodes comprises a first electrode having a distal end and a proximal end and a second electrode having a distal end and a proximal end, wherein a line perpendicular to the longitudinal axis across the concave surface intersects the first electrode at the proximal end and intersects the second electrode between the proximal and distal ends,
wherein each of the plurality of electrodes has an aspect ratio of its longitudinal length to its lateral width of at least 4:1.
2. An implantable medical lead according to
3. An implantable medical lead according to
4. An implantable medical lead according to
5. An implantable medical lead according to
6. An implantable medical lead according to
7. An implantable medical lead according to
8. An implantable medical lead according to
9. An implantable medical lead according to
10. An implantable medical lead according to
11. An implantable medical lead according to
12. A method for applying an electrical signal to a nerve, comprising:
implanting a medical lead according to
applying an electrical signal to the nerve via one or more of the plurality of electrodes.
13. A method according to
14. A method according to
15. A method according to
16. A method according to
|
This application is a U.S. National Stage filing under 35 U.S.C. 371 of copending PCT Application Serial No. PCT/US2010/039294, filed Jun. 21, 2010, which claims the benefit of priority to U.S. provisional patent application No. 61/218,456, filed Jun. 19, 2009, both of which applications are incorporated herein by reference to the extent that they do not conflict with the present disclosure.
This disclosure relates to implantable medical devices. More particularly, it relates to implantable medical leads.
Many implantable medical devices, such as neurostimulators, pacemakers and defibrillators, transmit electrical signals to provide therapy to a patient. Electrical signals generated by the devices may be delivered to tissue of a patient via electrodes disposed at a distal end portion of a medical lead.
Typically, nervous tissue is targeted by the electrical signals. However, broad targeting of a nerve can have undesired consequences. For example, if a nerve is targeted for treatment of pain, selective targeting of afferent fibers, as opposed to efferent fibers, would be desired to avoid undesired motor side effects. Accordingly, targeting selected fascicles of a nerve or a group of fascicles would be preferred over broad targeting of the nerve.
However, such selective targeting of nerve fascicles can be difficult, as the fascicles do not often run in a nerve through a straight line. A lead having electrode configurations capable of facilitating selective capture of desired fascicles of a nerve would be desirable.
The present disclosure describes, among other things, leads having an elongate arcuate distal portion with electrodes disposed along the concave surface of the arcuate distal portion. The arcuate distal portion may be implanted such that it partially surrounds a nerve. One or more electrodes may be employed to selectively apply an electrical signal to a particular set of nerve fibers (such as part of a fascicle), fascicle, or group of fascicles, of the nerve, such as those fascicles that tend to carry afferent sensory information.
In various embodiments, an implantable medical lead includes a lead body having a proximal portion having a longitudinal axis and an arcuate distal body portion extending in the direction of the longitudinal axis. The arcuate distal body portion has a concave surface. The lead includes a plurality of elongate electrodes disposed at the arcuate distal end portion of the lead body along the concave surface. The electrodes extend substantially parallel to the longitudinal axis of the lead body. Such an arrangement of the lead body and electrodes may be advantageous for stimulation of selective fascicles of a nerve when the lead is implanted such that the arcuate distal portion is substantially parallel to the nerve and the electrodes face the nerve.
These and various other features and advantages will be apparent from a reading of the following detailed description.
The drawings are not necessarily to scale. Like numbers used in the figures refer to like components, steps and the like. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the component in another figure labeled with the same number. In addition, the use of different numbers to refer to components is not intended to indicate that the different numbered components cannot be the same or similar.
In the following detailed description, reference is made to the accompanying drawings that form a part hereof, and in which are shown by way of illustration several specific embodiments of devices, systems and methods. It is to be understood that other embodiments are contemplated and may be made without departing from the scope or spirit of the apparatuses, systems and methods described herein. The following detailed description, therefore, is not to be taken in a limiting sense.
All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. Any definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” encompass embodiments having plural referents, unless the content clearly dictates otherwise.
As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
The terms “left,” “right,” “front,” “back,” “top,” “bottom,” “over,” “under,” and the like, if any, are used herein for descriptive purposes and not necessarily for describing permanent relative positions. It is to be understood that the terms so used are interchangeable under appropriate circumstances such that the embodiments described herein are, for example, capable of operation in other orientations than those illustrated or otherwise described herein. It will be further understood that directional terms, such as “longitudinal”, “lateral”, “transverse”, and the like, when used with regard to a lead, are intended to have approximate practical meanings in view of the limp nature of implantable medical leads and the environment of use, rather than precise geometrical meanings.
The recitation herein of numerical ranges by endpoints includes all numbers subsumed within that range (e.g., 1 to 5 includes at least 1, 1.5, 2, 2.75, 3, 3.80, 4 and 5) and any range within that range.
As used herein, “representative,” “exemplary,” and the like are used in the context of “providing an example” and do not necessarily indicate that the example provided is superior to, or more particularly suited for the intended purpose than, other potential examples.
As used herein, “substantially” means to a great extent or degree. For example, “substantially” may be within 10% or within 5%; e.g., a substantially circular shape may be a shape that has a radius that varies less than 10% around the circumference. That is, the largest radius to a point on the circumference is not more than 10% greater than the smallest radius to a point on the circumference. By way of further example, an object that is substantially parallel to a first axis may be parallel to within 10%. That is, the longitudinal axis of the object is not more than 18 degrees (10% of 180 degrees is 18 degrees) from parallel with the first axis. By way of further example, an object that extends substantially the length of another object may extend between 90% and 110% of the length of the other object.
The present disclosure describes, among other things, leads having an elongate arcuate distal portion with electrodes disposed along the concave surface of the arcuate distal portion. The arcuate distal portion may be implanted such that it partially surrounds a nerve. One or more electrodes may be employed to selectively apply an electrical signal to a particular set of nerve fibers (such as part of a fascicle), fascicle, or group of fascicles, of the nerve, such as those fascicles that tend to carry afferent sensory information.
It will be understood, however, that the leads described herein may be used with any electrical medical device, such as an electrical signal generator for neuro, cardiac, or gastric stimulation or a monitoring device for any suitable purpose.
Referring to
The lead 12 depicted in
The distal end portion 114 is arcuate, and can be defined by a radius that is greater than 0; i.e., distal end portion is not flat or planar. Distal end portion 114 has the arcuate form in its unstressed state; i.e., no external force is acting on lead 110 or distal end portion 114 to hold distal end portion 114 in its arcuate state. Distal end portion 114 may be sufficiently flexible to allow distal end portion 114 to be flattened or further curved; however, distal end portion 114 will not maintain a flattened or planar configuration without an external force acting thereon.
In embodiment depicted in
Disposed along the inner or concave surface 115 of distal end portion 114 are a plurality of electrodes 116 have a length L in the longitudinal direction of lead 110 and a width W in the lateral direction (see, e.g.,
The electrodes 116 depicted in
For example and with reference to
In
As further depicted in
Regardless of the electrode configuration of the lead, one or more electrodes may be selected for purposes of applying an electrical signal to a nerve. Preferably, the electrodes are selected to apply the electrical signal selectively to a particular fascicle or group of fascicles, such as a fascicle carrying afferent fibers.
The leads described herein may be used for any suitable purpose, such as treatment of chronic pain associated with a peripheral nerve, such as pain associated with carpal tunnel syndrome or with hernia operations. Carpal tunnel results from the chronic entrapment of the median nerve, which is composed of many different fascicles, which typically do not remain in the same arrangement throughout the length of the nerve. Chronic pain can result if the entrapment is not relieved or if surgical intervention to relieve the entrapment causes scar tissue or mild neuropathy. Herniorrhaphy is a surgical procedure for correcting a hernia. Hernias can occur in the abdomen, groin, and at the site of a previous surgery. There are several known repairs for hernias, and chronic pain can result from all types of repair procedures. This chronic post herniorrhaphy pain can result from damage to and entrapment of nerves innervating the surgical region. The formation of neuromas, scar tissue, and misplaced mesh may also be a cause for chronic pain. The affected nerves can include the ilioinguial, the iliohypogastric and the lateral femoral cutaneous. Leads having an arcuate distal end as described herein, when used as part of system 10 of
It will be understood that electrical signal parameters may be varied as desired for treating pain. Typically, the frequency, amplitude or pulse width of an electrical signal may be varied. An electrical signal having any suitable frequency for treating pain may be used to treat pain as described herein. For example, an electrical signal may have a frequency of about 0.5 Hz to 500 Hz (e.g., about 5 Hz to 250 Hz or about 10 Hz to 50 Hz). For example, the amplitude may be about 0.1 volts to 50 volts (e.g., about 0.5 volts to 20 volts or about 1 volt to 10 volts); for devices that the amps rather than voltage, one skilled in electronics understands the conversion from volts to amps for stimulation devices. An electrical signal may have any suitable pulse width. For example, the signal may have a pulse width of 10 microseconds to 5000 microseconds (e.g., about 100 microseconds to 1000 microseconds or about 180 microseconds to 450 microseconds). For some patients with some devices, the determination of the optimal location and parameters for stimulation occurs within days, for others, within hours or minutes.
Regardless of the use of the leads described herein, some features or aspects of some embodiments of leads having arcuate distal end portions are provided below. Leads having an arcuate distal end portion may be implanted into the patient either in their curved, unstressed state, or may be manipulated to a different shape during implantation and then returned to their unstressed state during use. For example, distal end portion may be wrapped tighter to allow insertion via a smaller introducer. Alternately, distal end portion may be deployed in a flattened state and then released. Shape retaining polymeric materials are particularly suited for distal end portions that are flattenable or wrappable.
The electrodes described herein have an overall elongated shape with an aspect ratio L:W (i.e., length in the longitudinal direction:width in the lateral direction) of at least 2:1; e.g., at least 4:1, at least 5:1 or at least 10:1. That is, the dimension of the electrode in the longitudinal direction is greater than, and in some embodiments, significantly greater than the dimension in the lateral direction. While depicted herein as rectangular, the exposed surface area of an elongate electrode may be any shape, such as oval or elliptical.
The active length of the electrodes, in the longitudinal direction, is at least about 0.5 mm and in some embodiments at least about 1 mm. The active length may be, for example, about 1 mm to about 50 mm (5 cm), in some embodiments about 2 mm to about 20 mm (2 cm). Particular example lengths include 2 mm, 5 mm, 10 mm (1 cm), 15 mm (1.5 cm). For some embodiments, electrode lengths of 3.8 mm (about 0.15 inch) or 2.54 mm (0.1 inch) are preferred. The overall length of the electrode, in the longitudinal direction, is, in some embodiments, at least 0.5 mm and in some embodiments at least about 1 mm.
In some embodiments, the width of the electrodes, in the lateral direction, is about 0.1 mm to about 5 mm, in other embodiments, about 0.5 mm to about 2 mm. For some embodiments, electrode widths of about 0.25 mm (about 0.0.1 inch) or about 0.5 mm (about 0.020 inch) are preferred.
The active surface areas of electrodes may be about 2 mm2 to about 100 mm2 (1 cm2), about 20 mm2 to about 50 mm2.
Inter-electrode distances are often about 3 mm, but other inter-electrode distances may be used such as about 1 mm, about 2 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 12 mm, about 14 mm, about 16 mm, about 18 mm, about 20 mm, about 25 mm, and about 30 mm. Inter-electrode distances refers to the lateral distance between electrodes (edge to edge) or to the longitudinal distance between electrodes (edge to edge).
The electrode arrangement may be in-line, staggered, or any other suitable configuration. Any suitable number of electrodes may be present on the arcuate distal end of the lead. For example, the arcuate distal end portion may have 4, 8, 10, 16 or more electrodes. By way of example, the number of electrodes along the lateral direction may be one or more, and may be 3, 4, or 5. By way of further example, the number of electrodes along the longitudinal direction may be one or more, and may be 2, 3, or 4. A large number of closely spaced electrodes will provide further options to selectively activate nerve fibers within a fascicle, fascicles or groups of fascicles.
Polyurethane is a suitable material for forming the lead body, although other materials such as silicone may be used. Electrical conductors extending between the proximal end and the distal end portions for supplying electrical current to the electrodes may be formed of coiled, braided or stranded wires comprising an electrical conductive material, e.g., MP35N or a platinum-iridium alloy. The electrodes are preferably formed of platinum, although other metals and metal alloys, such as gold or stainless steel, can be used. In some embodiments, non-metallic yet electrically conductive materials may be used as the electrodes and/or electrical conductors.
In various embodiments, a lead has a diameter in its proximal portion of about 5 mm or less, such as about 2 mm or less or about 1.5 mm. The arcuate distal end portion of a lead may have any suitable lateral dimension. For example, the arcuate distal end portion may have a lateral dimension of up to about 10 mm, but in most embodiments is less than about 5 mm.
One of skill in the art will understand that components described herein regarding a given embodiment or set of embodiments may readily be omitted, substituted, or added from, with, or to components of other embodiments or sets of embodiments, as appropriate or desirable.
Thus, embodiments of ELECTRODE ARRANGEMENTS FOR MEDICAL LEAD are disclosed. One skilled in the art will appreciate that the present invention can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation, and the present invention is limited only by the claims that follow.
Wahlstrand, Carl D., Seeley, Dale F., Molnar, Gabriela C.
Patent | Priority | Assignee | Title |
10065031, | Aug 27 2014 | ALEVA NEUROTHERAPEUTICS | Deep brain stimulation lead |
10166392, | Jul 30 2008 | Ecole Polytechnique Federale de Lausanne | Apparatus and method for optimized stimulation of a neurological target |
10201707, | Aug 27 2014 | ALEVA NEUROTHERAPEUTICS | Treatment of autoimmune diseases with deep brain stimulation |
10286210, | Nov 27 2013 | EBT MEDICAL, INC | Methods for improved treatment of overactive bladder |
10406350, | Nov 12 2008 | Ecole Polytechnique Federale de Lausanne | Microfabricated neurostimulation device |
10441779, | Aug 27 2014 | ALEVA NEUROTHERAPEUTICS | Deep brain stimulation lead |
10556107, | Nov 27 2013 | EBT MEDICAL, INC | Systems, methods and kits for peripheral nerve stimulation |
10695556, | Apr 01 2010 | Ecole Polytechnique Federale de Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
10702692, | Mar 02 2018 | ALEVA NEUROTHERAPEUTICS | Neurostimulation device |
10952627, | Jul 30 2008 | Ecole Polytechnique Federale de Lausanne | Apparatus and method for optimized stimulation of a neurological target |
10966620, | May 16 2014 | ALEVA NEUROTHERAPEUTICS | Device for interacting with neurological tissue and methods of making and using the same |
11123548, | Nov 12 2008 | Ecole Polytechnique Federale de Lausanne | Microfabricated neurostimulation device |
11167126, | Aug 27 2014 | ALEVA NEUROTHERAPEUTICS | Deep brain stimulation lead |
11266830, | Mar 02 2018 | ALEVA NEUROTHERAPEUTICS | Neurostimulation device |
11311718, | May 16 2014 | Aleva Neurotherapeutics SA | Device for interacting with neurological tissue and methods of making and using the same |
11426579, | Nov 27 2013 | EBT MEDICAL, INC | Systems, methods and kits for peripheral nerve stimulation |
11446489, | Nov 27 2013 | EBT Medical, Inc. | Method for treating a patient having a pelvic floor dysfunction |
11529513, | Nov 27 2013 | EBT MEDICAL, INC | Neuromodulation system |
11633593, | Nov 27 2013 | EBT Medical, Inc. | Treatment of pelvic floor disorders using targeted lower limb nerve stimulation |
11730953, | Aug 27 2014 | ALEVA NEUROTHERAPEUTICS | Deep brain stimulation lead |
11738192, | Mar 02 2018 | ALEVA NEUROTHERAPEUTICS | Neurostimulation device |
11766560, | Apr 01 2010 | Ecole Polytechnique Federale de Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
9884187, | May 21 2015 | EBT MEDICAL, INC | Method for treating a patient having a pelvic floor dysfunction or disorder |
Patent | Priority | Assignee | Title |
3804098, | |||
4774952, | Jun 20 1985 | Medtronic, Inc. | Cardioversion and defibrillation lead |
5843148, | Sep 27 1996 | Medtronic, Inc | High resolution brain stimulation lead and method of use |
7515968, | Apr 28 2006 | Medtronic, Inc | Assembly method for spinal cord stimulation lead |
7672734, | Dec 27 2005 | Boston Scientific Neuromodulation Corporation | Non-linear electrode array |
7769472, | Jul 29 2005 | Medtronic, Inc | Electrical stimulation lead with conformable array of electrodes |
7996092, | Jan 16 2007 | SPR THERAPEUTICS, INC | Devices, systems, and methods employing a molded nerve cuff electrode |
20010025192, | |||
20040117728, | |||
20070027514, | |||
20080027524, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Jun 21 2010 | Medtronic, Inc. | (assignment on the face of the patent) | / | |||
Nov 28 2011 | WAHLSTRAND, CARL D | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 027317 | /0911 | |
Nov 28 2011 | MOLNAR, GABRIELA C | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 027317 | /0911 | |
Nov 29 2011 | SEELEY, DALE F | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 027317 | /0911 |
Date | Maintenance Fee Events |
Feb 13 2017 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Jan 21 2021 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Dec 18 2024 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Aug 13 2016 | 4 years fee payment window open |
Feb 13 2017 | 6 months grace period start (w surcharge) |
Aug 13 2017 | patent expiry (for year 4) |
Aug 13 2019 | 2 years to revive unintentionally abandoned end. (for year 4) |
Aug 13 2020 | 8 years fee payment window open |
Feb 13 2021 | 6 months grace period start (w surcharge) |
Aug 13 2021 | patent expiry (for year 8) |
Aug 13 2023 | 2 years to revive unintentionally abandoned end. (for year 8) |
Aug 13 2024 | 12 years fee payment window open |
Feb 13 2025 | 6 months grace period start (w surcharge) |
Aug 13 2025 | patent expiry (for year 12) |
Aug 13 2027 | 2 years to revive unintentionally abandoned end. (for year 12) |